SPIROTHIETAN NUKLEOSIDE

European patent · EP3676276 · In force

Register entry

Publication number
EP3676276
Application number
EP18759138
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Aug 31, 2018
Published
Jul 8, 2020
Granted
Dec 8, 2021
Protection ends at the latest
Aug 30, 2038
Next annual fee due
Aug 31, 2026
IPC classes
C07H 19/06 (2006.01)
A61K 31/7068 (2006.01)
A61K 31/7072 (2006.01)
A61K 31/7076 (2006.01)
A61K 31/708 (2006.01)
C07H 19/10 (2006.01)
C07H 19/16 (2006.01)
C07H 19/20 (2006.01)
A61P 31/14 (2006.01)
Priority
EP 17189097 01.09.2017
PCT application
PCT/EP2018/073505 31.08.2018
PCT publication
WO2019/043177 07.03.2019
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Sep 1, 2025

    Change

    Published in Swissreg on 01.09.2025

  2. Sep 3, 2024

    Change

    Published in Swissreg on 03.09.2024

  3. Sep 1, 2023

    Change

    Published in Swissreg on 01.09.2023

  4. Oct 19, 2022

    Change

    Published in Swissreg on 19.10.2022

  5. Sep 1, 2022

    Change

    Published in Swissreg on 01.09.2022

  6. Dec 8, 2021

    Granted

    Published in Swissreg on 08.12.2021

Parties

Holder

Janssen Pharmaceutica NV

Turnhoutseweg 30, 2340 Beerse, BE

Inventor

TAHRI, Abdellah

2340 Beerse, BE

RABOISSON, Pierre Jean-Marie Bernard

2340 Beerse, BE

BONFANTI, Jean-François

92787 Issy-les-Moulineaux Cedex 9, FR

JONCKERS, Tim Hugo Maria

2340 Beerse, BE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.